Cryotherapy for the Prevention of Taxane-Induced Sensory Neuropathy of the Hands and Feet in Breast Cancer Patients

Inclusion Criteria:

Patients >= 18 years of age with a diagnosis of breast cancer
Patients receiving 12-18 weeks of chemotherapy with a taxane-based regimen (4 cycles of weekly x 3 paclitaxel or 4-6 cycles of docetaxel every 3 weeks)
Absence of sensory peripheral neuropathy, skin or nail disorders at the start of treatment
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
Ability to complete questionnaires by themselves or with assistance
Ability to give signed informed consent

Exclusion Criteria:

History of prior sensory/motor peripheral neuropathy from any cause
History of prior Raynaud's phenomenon
History of cryoglobulinemia
Active peripheral vascular disease
Cold intolerance
Prior exposure to neurotoxic chemotherapy in the last 10 years
Hand-foot syndrome
Tumor metastasis in bone, soft tissue, or skin of the hands or feet
Absence of one or more fingers or toes
Prior exposure to taxane chemotherapy